Centene (CNC, Managed Health Care) Stock Valuation & Fair Value Significantly overvalued
Centene (CNC, Managed Health Care) trades at a blended P/E of 24.0 — about 40% above its historical normal valuation — with a forward growth estimate of 36.0% and a PEG of 0.67. Analysts' one-year estimates have been hit 64% of the time.
Valuation flags
- Overvalued by 40%
Verdict history
tickerseer's rating moved from trading above fair value (2026-06-03) to significantly overvalued (2026-07-14).
Frequently asked questions
Is Centene stock overvalued?
At a blended P/E of 24.0 versus its historical normal P/E of 17.2, Centene trades about 40% above its typical valuation, with a PEG of 0.67 on 36.0% forward growth — tickerseer currently rates it significantly overvalued.
What is Centene's fair value and PEG?
Centene trades at a blended P/E of 24.0 against a historical normal P/E of 17.2, a PEG of 0.67, and a forward growth estimate of 36.0%.
Has tickerseer's rating of Centene changed?
tickerseer's rating moved from trading above fair value (2026-06-03) to significantly overvalued (2026-07-14).
Industry: Managed Health Care. Create a free account to unlock the full analysis — the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.